drugset / Trial / NCT01532102

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

NCT01532102 ↗

Phase 1/2 Completed 24 enrolled Anaconda Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).

Timeline

Start
2012-02-28
Primary completion
2013-05-06
Completion
2013-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AP611074 Small molecule 100 mg Topical